Interestingly, targeting one such proteasome-regulating kinase, DYRK2, in vivo dramatically reduced tumor burden in multiple myeloma and triple-negative breast cancer (TNBC) mouse models [18–21]. This evidence concerns the gene DYRK2 and AL amyloidosis.